Additionally, CCR4 antagonist reduced the tumor growth of CCL17high and CCL22high tumors, suggesting that CCR4 blockade is beneficial not only for controlling Tregs infiltration and reversing CD8 T cell exhaustion, but also for restricting tumor growth which can be particularly beneficial in those who develop sorafenib resistance. Here, CD8A is linked to neoplasm.